Ibogaine vs. Psilocybin vs. Ketamine: An Honest Comparison for People Who've Already Done the Research
You've probably already read the headlines. Ketamine clinics on every corner. Psilocybin retreats proliferating across Oregon and Colorado. A growing body of research suggesting these compounds do something genuinely useful for the brain. And somewhere in your reading, you encountered ibogaine — harder to access, longer in duration, and carrying a reputation that is equal parts fascinating and intimidating.
If you're trying to figure out which of these options is actually right for what you're dealing with, this post is for you. Not a promotional pitch for any of them — a clear-eyed breakdown of what each compound does, how it works biologically, how long it lasts, and what clinical context it's best suited to. The goal is to help you self-select based on what you actually need, not what's most available or most discussed.
They Are Not the Same Category of Medicine
This might be the most important thing to understand before anything else. Psilocybin, ketamine, and ibogaine are often grouped together under the umbrella of "psychedelic-assisted therapy," which is convenient shorthand but obscures real pharmacological differences that matter clinically.
Ketamine is a dissociative anesthetic. It works primarily by blocking NMDA receptors, which interrupts glutamate signaling and produces rapid but relatively short-lived changes in mood and cognition. Psilocybin is a classical serotonergic psychedelic — it works by strongly agonizing the 5-HT2A receptor and produces an acute perceptual and emotional experience lasting 4 to 6 hours. Ibogaine is neither of these things. It is classified as an oneirogen — meaning it induces dreamlike states rather than hallucinations — and it acts simultaneously across a wide range of receptor systems in ways that classical psychedelics simply do not.
Lumping them together is a bit like grouping aspirin, prednisone, and surgery because they all reduce inflammation. Mechanistically, they are doing very different things.
How Ketamine Works — and Why Its Effects Have a Ceiling
Ketamine's appeal is speed and accessibility. A single infusion can lift depression within hours, which is genuinely remarkable compared to antidepressants that take weeks. It is FDA-cleared (via the intranasal esketamine formulation, Spravato) for treatment-resistant depression, and infusion clinics have made it the most accessible of the three options discussed here.
The mechanism centers on NMDA receptor blockade, which triggers a downstream cascade involving AMPA receptor activation and BDNF release. This creates a burst of synaptic plasticity, which is thought to underlie the antidepressant effect. Research published in Nature has confirmed that ketamine reopens what neuroscientists call the "social reward learning critical period" — a window of neuroplastic flexibility that closes in adulthood — with effects lasting approximately one week in animal models (Nardou et al., Nature, 2023).
That one-week window is informative. The acute experience lasts 30 to 90 minutes. The antidepressant effect can last days to a few weeks. Many patients require repeated infusions to sustain benefit. For acute relief, ketamine is genuinely useful. For deep structural reset, its depth is limited by the brevity of its action and the narrowness of its receptor engagement.
Ketamine does not meaningfully upregulate GDNF (Glial Cell line-Derived Neurotrophic Factor). This distinction matters, because GDNF plays a specific role in protecting and restoring dopaminergic neurons — the circuit most implicated in motivation, anhedonia, and addiction.
How Psilocybin Works — and Where It Excels
Psilocybin converts to psilocin in the body and acts as a potent 5-HT2A receptor agonist. This produces a 4 to 6 hour experience characterized by perceptual changes, emotional amplification, and a disruption of the default mode network — the brain's self-referential processing system — that often facilitates psychological insight.
The clinical evidence for psilocybin is increasingly strong. A landmark study in JAMA Psychiatry (Davis et al., 2021) found large reductions in major depressive disorder symptoms following two sessions of psilocybin-assisted therapy, with effects maintained at one-month follow-up. Research from Johns Hopkins and Imperial College London has demonstrated robust results in treatment-resistant depression, end-of-life anxiety, and addiction.
In the Nardou et al. mouse study referenced above, psilocybin reopened the social reward learning critical period with effects lasting approximately two to three weeks — longer than ketamine, but shorter than ibogaine. The experience itself requires psychological preparation and support, and not everyone finds the perceptual intensity manageable.
Psilocybin is a strong option for people dealing with depression, existential distress, grief, and certain anxiety presentations. It produces genuine neuroplastic changes and, when combined with quality psychotherapeutic support, can catalyze meaningful psychological reorganization. Its limitations become relevant when the presenting problem is neurobiological rather than primarily psychological — when the issue is not how you think about things but how your reward circuitry, dopamine system, or withdrawal physiology is actually functioning.
How Ibogaine Works — and Why It Occupies a Different Category Entirely
Ibogaine is derived from the root bark of Tabernanthe iboga, a plant used for centuries in the Bwiti tradition of Gabon and surrounding regions. Unlike classical psychedelics, ibogaine and its primary metabolite noribogaine have very low affinity for the 5-HT2A receptor. They do not produce typical serotonergic hallucinations. The experience is described as oneirogenic — deeply dreamlike, introspective, and narrative in quality, with eyes-open visual acuity generally preserved (González Espejito et al., PLOS ONE, 2025).
The pharmacological profile is genuinely unusual. Ibogaine simultaneously engages kappa-opioid receptors, NMDA receptors, sigma-1 receptors, serotonin and dopamine transporters, nicotinic acetylcholine receptors, and more. This "polypharmacy" or "matrix pharmacology" effect is increasingly understood as central to why ibogaine produces outcomes that narrower-acting compounds do not (Ona et al., 2023).
The GDNF and BDNF Distinction
Here is where ibogaine separates itself most clearly from the other two options. Research published in Frontiers in Pharmacology (Marton et al., 2019) demonstrated that ibogaine administration produces a significant, dose-dependent upregulation of both GDNF and BDNF transcripts in brain regions central to dopaminergic function — specifically the ventral tegmental area (VTA), nucleus accumbens, prefrontal cortex, and substantia nigra.
GDNF upregulation in the VTA is particularly significant. This is the region where dopaminergic neurons originate. GDNF has long been studied for its neuroprotective and restorative effects on these neurons, and its role in attenuating drug-seeking behavior in animal models is well-established. Psilocybin produces BDNF changes; ibogaine produces changes in both BDNF and GDNF, in regions that regulate motivation, reward, and the biological substrate of addiction.
Noribogaine, ibogaine's long-acting metabolite, has been classified as a "psychoplastogen" — it promotes neuritogenesis (growth of new neural processes) in cultured cortical neurons (Ly et al., 2018). This structural plasticity, combined with GDNF and BDNF upregulation, is likely why ibogaine produces effects that can persist for months to years from a single treatment session.
Duration and the Critical Period Window
The Nardou et al. Nature study provided a striking data point: ibogaine reopened the social reward learning critical period in mice with effects still detectable at four weeks — outlasting psilocybin (two to three weeks), LSD (three weeks), and ketamine (one week). The proportionality held across human subjective experience durations: ketamine lasts 30 to 90 minutes, psilocybin 4 to 6 hours, ibogaine 24 to 36 hours. More time inside the neuroplastic window appears to correspond with more durable downstream change.
The ibogaine experience itself unfolds in three recognizable phases. The acute phase (approximately 1 to 8 hours) involves dreamlike, often visionary content. The evaluative phase (roughly 8 to 20 hours) involves a more reflective, introspective quality — many describe reviewing their lives with unusual clarity and emotional access. The residual phase (20 to 72 hours) involves reintegration as effects gradually resolve (Cherian et al., Nature Medicine, 2024).
What the Clinical Evidence Shows
The most rigorous recent data comes from the Stanford MISTIC study (Cherian et al., Nature Medicine, 2024), a prospective observational study of 30 Special Operations Forces veterans with predominantly mild traumatic brain injury. Following magnesium-ibogaine treatment, participants showed large effect sizes for functioning (Cohen's d = 2.20 at one month), PTSD (d = 2.54), depression (d = 2.80), and anxiety (d = 2.13). These are unusually large effects by psychiatric research standards. There were no unexpected serious adverse events.
The treatment also requires respect. Ibogaine prolongs the cardiac QT interval, and fatalities have occurred in poorly screened or unsupervised settings. Magnesium coadministration and continuous cardiac monitoring substantially reduce this risk. Medical screening is non-negotiable. This is not a compound to approach without appropriate clinical infrastructure.
A Practical Framework: Which Option Fits What
Rather than declaring a winner, it is more useful to match the tool to the problem.
Ketamine fits best when the primary goal is rapid relief of acute depressive symptoms, when you need something that can be accessed within the conventional healthcare system, or when shorter-duration intervention is indicated by circumstance. Its neuroplastic effects are real but limited in depth and duration.
Psilocybin fits best when the presenting challenge is psychological — depression, existential distress, grief, certain anxiety presentations, or psycho-spiritual stagnation. When psychological insight combined with neuroplastic flexibility is the mechanism you're trying to activate, psilocybin offers a well-studied, evidence-backed option. It requires preparation, a supportive set and setting, and integration work afterward.
Ibogaine fits best when the problem is primarily neurobiological. Opioid dependence, stimulant addiction, anhedonia driven by depleted dopaminergic function, complex PTSD with neurological overlap, or TBI sequelae are the presentations where ibogaine's unique receptor profile, GDNF/BDNF upregulation, and extended neuroplastic window offer something the other two options cannot replicate. It is also the logical choice when shorter-acting compounds have already been tried and the relief did not hold.
The depth of reset with ibogaine comes at the cost of intensity and duration. A full ibogaine treatment is not a comfortable afternoon. It is a significant neurological and psychological event that requires medical supervision, careful preparation, and dedicated integration support afterward.
The Question of Safety and Serious Consideration
All three compounds carry risks. Ketamine carries risks of dissociation, misuse potential, and bladder toxicity with heavy recreational use. Psilocybin carries risks of psychological difficulty, particularly in people with predispositions to psychosis. Ibogaine carries cardiac risks that require proper screening — a normal QTc interval, no contraindicated medications, and no structural cardiac conditions are prerequisites.
When ibogaine is administered in a properly structured clinical environment with cardiac monitoring, magnesium supplementation, medical-grade screening, and experienced supervision, the risk profile is manageable. The Stanford MISTIC study — conducted with rigorous protocols — reported no unexpected serious adverse events across 30 participants. Context and clinical infrastructure matter enormously.
FAQ
Can I combine these approaches, or do they interfere with each other?
Sequencing is possible but requires careful planning. Ibogaine has significant drug interactions, particularly with serotonergic medications and opioids, and requires a washout period before treatment. Combining sessions of psilocybin and ibogaine in the same program (without appropriate washout) carries real risks. A qualified medical team should guide any multi-modal approach.
Is ibogaine appropriate if I don't have an addiction?
Yes. While ibogaine's most studied application is opioid use disorder, a growing body of evidence and clinical experience supports its use for PTSD, TBI, depression, and general neurological restoration in people without addiction histories. The mechanisms that make it effective for addiction — GDNF upregulation, deep neuroplastic reset, dopaminergic restoration — are relevant to a range of neuropsychiatric presentations.
How long do the effects of ibogaine last?
This varies by individual and indication. In studies of addiction, many participants report significantly reduced or eliminated cravings lasting months to over a year from a single session. In the MISTIC TBI study, significant functional improvements were still present at the one-month follow-up (the study's endpoint). The neuroplastic window appears to remain open for at least four weeks, which is why integration work during that period is critical.
Why isn't ibogaine legal everywhere if the evidence is this promising?
Ibogaine is classified as Schedule I in the United States, reflecting historical categorization rather than current scientific understanding. Legal treatment is available in several countries, including Mexico, Portugal, South Africa, New Zealand, and parts of Southeast Asia. The legal landscape is evolving — New Zealand deregulated ibogaine in 2023, and there is growing momentum toward reclassification elsewhere as the evidence base strengthens.
What does cardiac screening involve before ibogaine treatment?
Standard pre-treatment cardiac screening includes a resting 12-lead ECG to assess QTc interval, a review of all current medications for potential interactions, and a cardiovascular history. People with prolonged QTc, certain arrhythmias, uncontrolled hypertension, or structural cardiac disease are generally not candidates. Magnesium supplementation before and during treatment is now standard practice at responsible clinical centers.
About Nomena
Nomena is a medically supervised ibogaine treatment center operating in Southeast Asia, designed for people who approach this decision with the same rigor they bring to everything else. Our protocols include comprehensive pre-treatment cardiac screening, continuous ECG monitoring during treatment, magnesium coadministration, experienced medical oversight, and structured integration support.
We work with a small number of guests at a time, which means individualized care — not a volume-based model. If you've read the research, asked the hard questions, and are trying to determine whether ibogaine is the right fit for your specific situation, we'd welcome a conversation.
Citations
1. Marton S, González B, Rodríguez-Bottero S, et al. Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. Frontiers in Pharmacology. 2019;10:193. https://doi.org/10.3389/fphar.2019.00193
2. Nardou R, Sawyer E, Song YJ, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023;618:790–798. https://doi.org/10.1038/s41586-023-06204-3
3. Cherian KN, Keynan JN, Anker L, et al. Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine. 2024;30:373–381. https://doi.org/10.1038/s41591-023-02705-w
4. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
5. González Espejito F, Esteban Rodríguez L, Pedrero Pérez EJ, et al. The Ibogaine Experience Scale (IES): Development and psychometric properties of a multidimensional measure of ibogaine's subjective effects. PLOS ONE. 2025;20(10):e0333296. https://doi.org/10.1371/journal.pone.0333296
6. Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Reports. 2018;23(11):3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022
7. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine. 2022;387:1637–1648. https://doi.org/10.1056/NEJMoa2206443
8. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235:399–408. https://doi.org/10.1007/s00213-017-4771-x